๋ฐํ ๋ฏธ๋
> **๋ฐํ ๋ฏธ๋**์ ๊ฐ๋ ฅํ ์ํ-2 ์๋๋ ๋ ๋ฆฐ ์์ฉ์ ๋ก, ์ฃผ๋ก ๋ง ์ํ์์ ๊น์ ์ง์ ๋ฐ ์งํต ํจ๊ณผ๋ฅผ ์ํด ์ฌ์ฉ๋ฉ๋๋ค. * **์ญ๊ฐ:** ์์ผ๋ผ์ง๋ณด๋ค ์ฝ 50~100๋ฐฐ ๋ ๊ฐ๋ ฅํฉ๋๋ค. * **์์ ์ฉ๋:** ๋ง์ ๊ธฐ๋ฆฝ ์ง์ , ์๊ท๋ชจ ์์ ๋ฐ ์งํต(ํนํ ์ฐํต)์ ๋๋ฆฌ ์ฌ์ฉ๋ฉ๋๋ค. ์, ์ํ ๋ฐ์ถ๋๋ฌผ, ๋ํ๊ณผ ๋๋ฌผ ๋ฐ ์กฐ๋ฅ์๋ ํ๊ฐ ์ธ ์ฉ๋๋ก ์ฌ์ฉ๋ ๋ฐ ์์ต๋๋ค. * **์ค์ ์ฃผ์์ฌํญ:** ๋ง์ด ๊น๊ฒ ์ง์ ๋ ๊ฒ์ฒ๋ผ ๋ณด์ด๋๋ผ๋ ์ธ๋ถ ์๊ทน์ ๊ฐ์๊ธฐ ๋ฐ์(์: ๋ฐ์ฐจ๊ธฐ)ํ ์ ์์ต๋๋ค. ์คํผ์ค์ด๋(์: ๋ถํ ๋ฅดํ๋)๋ฅผ ์ถ๊ฐํ๋ฉด ์ด๋ฌํ ๋๋ ๋ฐ์์ ์ํํ๊ณ ์ง์ ์ ์ง์ ๋์ด๋ ๋ฐ ๋์์ด ๋ ์ ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : Detomidine acts as a potent and highly specific agonist at **alpha-2 adrenergic receptors** in the central and peripheral nervous systems. * **Sedation & Analgesia:** Activation of presynaptic alpha-2 receptors in the locus coeruleus and dorsal horn of the spinal cord โ inhibition of norepinephrine release โ decreased sympathetic outflow, resulting in profound sedation, muscle relaxation, and analgesia. * **Cardiovascular Effects:** Initial activation of peripheral postsynaptic alpha-2 receptors โ transient vasoconstriction and **hypertension** โ compensatory vagal reflex โ profound **bradycardia** and potential AV block. Central sympatholytic effects then lead to a prolonged decrease in blood pressure.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Anesthesia ยท 0.01 mg/kg IM ยท IM ยท once ยท Followed by propofol at 3-5 mg/kg IV.
- Analgesia ยท 0.005-0.05 mg/kg IV or IM q3-6 hours (once) ยท IV/IM ยท q3-6h ยท once
- Anesthesia ยท 0.01 mg/kg IM ยท IM ยท once ยท Followed by propofol at 3-5 mg/kg IV.
- Analgesia ยท 0.005-0.05 mg/kg IV or IM q3-6 hours (once) ยท IV/IM ยท q3-6h ยท once
- Sedation/analgesia ยท 30-60 micrograms/kg (0.03-0.06 mg/kg) IV or IM ยท IV/IM ยท once ยท Not FDA-approved.
- Analgesia ยท 0.01 mg/kg IV ยท IV ยท once ยท 1/2 hour ยท Withdrawal times: Milk = 72 hours; Slaughter = 7 days.
- Sedation/analgesia ยท 20-40 micrograms/kg (0.02-0.04 mg/kg) IV or IM ยท IV/IM ยท once ยท IV only for analgesia. Lower dose provides 30-90 min sedation/30-45 min analgesia. Higher dose provides 90-120 min sedation/45-75 min analgesia.
- Sedation/analgesia (Sublingual Gel) ยท 0.04 mg/kg (0.018 mg/lb) (0.040 mg/kg) placed beneath the tongue ยท Sublingual ยท once ยท Not meant to be swallowed.
- Marked abdominal pain (not surgical candidates or long transport) ยท 0.01-0.02 mg/kg (10-20 micrograms/kg) IV or IM ยท IV/IM ยท once
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Preexisting AV or SA heart block
- Severe coronary insufficiency
- Cerebrovascular disease
- Severe respiratory disease
- Chronic renal failure
์ด์๋ฐ์
- Initial blood pressure increase (hypertension)
- Profound bradycardia and heart block (AV block)
- Piloerection
- Sweating
- Ataxia
- Salivation
- Slight muscle tremors
- Penile prolapse
- Decreased gastrointestinal motility
์ฝ๋ฌผ ์ํธ์์ฉ
- Other Alpha-2 Agonists (e.g., xylazine, medetomidine, clonidine) ยท Not recommended to be used together as effects may be additive.
- Anesthetics, Opiates, Sedative/Hypnotics ยท Effects may be additive; dosage reduction required. Increased risk for arrhythmias with thiopental, ketamine, or halothane.
- Epinephrine ยท Do not use to treat cardiac effects caused by detomidine, as epinephrine possesses alpha agonist effects.
- Phenothiazines (e.g., acepromazine) ยท Severe hypotension can result.
- Potentiated Sulfonamides (e.g., trimethoprim/sulfa) ยท Fatal dysrhythmias may occur if used with intravenous potentiated sulfonamides.
๋ชจ๋ํฐ๋ง
- Level of sedation and analgesia
- Cardiac rate and rhythm
- Blood pressure (if indicated)
๊ณผ์ฉ๋
> **Toxicity Profile:** * Tolerated by horses at 5X the high dose level (0.2 mg/kg). * Doses of 10-40X recommended can cause severe respiratory and cardiovascular changes that can become irreversible and cause death. * **Reversal:** Alpha-2 antagonists such as **atipamezole** (50-100 micrograms/kg) or **yohimbine** can be successfully used to reverse some or all effects of inadvertent overdoses.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.